gemcitabine,cisplatin,carboplatin,enfortumab,pembrolizumab
astellas,seagen,merck
['bladder', 'urothelial', 'pembro', 'ev103']
beautiful update from brilliant of #ev103 cohort a results 45 pts w met urothelial cancer tx d w ev-pembro, 73% orr w 15% cr!! 41% of patients without progression at 2 years this has not been seen for patients w #bladdercancer. #asco23 
I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PATXe